Adalimumab – December 2024

Adalimumab (IMID): Injection 20 mg in 0.2 mL pre filled syringe, Injection 40 mg in 0.4 mL pre filled syringe, Injection 40 mg in 0.4 mL pre filled pen, Injection 80 mg in 0.8 mL pre filled syringe, Injection 80 mg in 0.8 mL pre filled pen; Humira® – March 2024 – December 2024

Brand names:
- Humira®
Pharmaceutical Company:
- AbbVie Pty Ltd
Condition/Indication: Immune-mediated inflammatory disease (IMID)
Meeting Date: December 2024
Public Summary Document (PSD) March 2024 December 2024 PBAC Meetings - (PDF 664KB)
Public Summary Document (PSD) March 2024 December 2024 PBAC Meetings - (Word 118KB)

Related Public Summary Documents

Adalimumab – March 2024

Last updated

30 May 2025